Bioaffinity detection of pathogens on surfaces

Wark, Alastair W.; Lee, Jae-Young; Kim, Suhee; Faisal, Shaikh Nayeem; Lee, Hye Jin

doi:10.1016/j.jiec.2010.01.061

Cited by 25 publications

(6 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These characteristics make them ideal candidates for designing and developing point‐of‐care tests (POCT) to diagnose and combat COVID‐19 and other future pandemics. Briefly, in comparison to molecular‐based assays or diagnostic technologies, aptameric sensors have advantages such as (i) ease of generation for several targets (including toxins and non‐nucleic acid targets; Radom et al, 2013 ); (ii) non‐requirement of sample preparation (Wark et al, 2010 ); (iii) the capacity to develop biosensing technologies that are simple, rapid, less expensive, and can be used in real‐time (Garibyan & Avashia, 2013 ).…”

Section: Future Perspectivementioning

confidence: 99%

Aptamers as promising nanotheranostic tools in the COVID‐19 pandemic era

Dzuvor

Tettey

Danquah

2022

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

The emergence of SARS‐COV‐2, the causative agent of new coronavirus disease (COVID‐19) has become a pandemic threat. Early and precise detection of the virus is vital for effective diagnosis and treatment. Various testing kits and assays, including nucleic acid detection methods, antigen tests, serological tests, and enzyme‐linked immunosorbent assay (ELISA), have been implemented or are being explored to detect the virus and/or characterize cellular and antibody responses to the infection. However, these approaches have inherent drawbacks such as nonspecificity, high cost, are characterized by long turnaround times for test results, and can be labor‐intensive. Also, the circulating SARS‐COV‐2 variant of concerns, reduced antibody sensitivity and/or neutralization, and possible antibody‐dependent enhancement (ADE) have warranted the search for alternative potent therapeutics. Aptamers, which are single‐stranded oligonucleotides, generated artificially by SELEX (Evolution of Ligands by Exponential Enrichment) may offer the capacity to generate high‐affinity neutralizers and/or bioprobes for monitoring relevant SARS‐COV‐2 and COVID‐19 biomarkers. This article reviews and discusses the prospects of implementing aptamers for rapid point‐of‐care detection and treatment of SARS‐COV‐2. We highlight other SARS‐COV‐2 targets (N protein, spike protein stem‐helix), SELEX augmented with competition assays and in silico technologies for rapid discovery and isolation of theranostic aptamers against COVID‐19 and future pandemics. It further provides an overview on site‐specific bioconjugation approaches, customizable molecular scaffolding strategies, and nanotechnology platforms to engineer these aptamers into ultrapotent blockers, multivalent therapeutics, and vaccines to boost both humoral and cellular immunity against the virus. This article is categorized under: Therapeutic Approaches and Drug Discovery > Emerging Technologies Diagnostic Tools > Biosensing Therapeutic Approaches and Drug Discovery > Nanomedicine for Infectious Disease Therapeutic Approaches and Drug Discovery > Nanomedicine for Respiratory Disease

show abstract

Section: Future Perspectivementioning

confidence: 99%

Aptamers as promising nanotheranostic tools in the COVID‐19 pandemic era

Dzuvor

Tettey

Danquah

2022

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…Hence, it can be developed for detection or testing for COVID-19 cases at home and this will be reduced travelling to clinical/healthcare facilities which could contribute to rapid diseases transmission and escalation. Similar to molecular diagnostics, aptasensors are highly specific, sensitive and can be applied or incorporated into multiplex systems or applications 124,125,[128][129][130] .…”

Section: Aptameric Nanosensors For Sars Coronavirus Detectionmentioning

confidence: 99%

Rethinking Aptamers as Nanotheranostic Tools for SARS-COV-2 and COVID-19 Infection

Dzuvor¹

2020

Preprint

View full text Add to dashboard Cite

The novel coronavirus named by WHO and Coronavirus Study Group (CSG) as SARS-COV-2 is the etiological agent of the newly emerged Coronavirus disease (COVID-19). COVID-19 has become a pandemic threat as the WHO declared it a public health emergency of international concern. Early and precise detection of the virus is important for effective diagnosis and treatment. Various testing kits and assays, including real-time reverse Transcriptase PCR, thermal screening guns, ELISA-based immunoassays, and Point-of-Care (POC), have been implemented or are being explored to detect the virus and/or characterise cellular and antibody responses to the infection. However, these approaches have inherent limitations such as non-specificity, high cost, characterize by long turnaround times for test results, and can be labour intensive. Aptamers, which are single-stranded oligonucleotides, generated artificially by SELEX (Evolution of Ligands by Exponential Enrichment) may offer the capacity to generate high affinity bioprobes for monitoring relevant SARS-COV 2 and COVID-19 biomarkers. This article discusses the prospects of implementing aptasensing technologies for rapid point-of-care detection of SARS-COV-2.

show abstract

“…quartz crystal microbalance; and electrochemical methods e.g. amperometry, voltammetry and impedance (Wark et al , 2010). The following section aims to discuss the different approaches to constructing an impedimetric pathogen immunosensor.…”

Section: Impedimetric Bacterial and Viral Immunosensorsmentioning

confidence: 99%